Immanaz 200 mg Powder for solution for injection
PDF Leaflet Revision Date: 14 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of invasive aspergillosis and serious Candida infections.
Dosage (summary)
Loading: 6 mg/kg every 12 hours for 24 hours; Maintenance: 3-4 mg/kg every 12 hours.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy; discontinue breastfeeding during treatment.
Key Drug Interactions
- CYP3A4 substrates (e.g., terfenadine, astemizole)
- Rifampicin
- Carbamazepine
- Phenobarbital
Contraindications
- Hypersensitivity to voriconazole
- Severe hepatic impairment (Child-Pugh Class C)
- Prolonged QT syndrome
Common side effects
- Visual disturbances
- Nausea
- Vomiting
- Rash
- Headache
Counselling Points
- Use effective contraception during treatment.
- Avoid sun exposure; use sunscreen.
- Monitor for visual changes.
Serious warnings
- QTc prolongation risk
- Hepatic toxicity
- Severe skin reactions
Important Disclaimer
The Immanaz 200 mg Powder for solution for injection professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
